These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. A Dual-Modality Herpes Simplex Virus 2 Vaccine for Preventing Genital Herpes by Using Glycoprotein C and D Subunit Antigens To Induce Potent Antibody Responses and Adenovirus Vectors Containing Capsid and Tegument Proteins as T Cell Immunogens. Awasthi S; Mahairas GG; Shaw CE; Huang ML; Koelle DM; Posavad C; Corey L; Friedman HM J Virol; 2015 Aug; 89(16):8497-509. PubMed ID: 26041292 [TBL] [Abstract][Full Text] [Related]
9. Protection provided by a herpes simplex virus 2 (HSV-2) glycoprotein C and D subunit antigen vaccine against genital HSV-2 infection in HSV-1-seropositive guinea pigs. Awasthi S; Balliet JW; Flynn JA; Lubinski JM; Shaw CE; DiStefano DJ; Cai M; Brown M; Smith JF; Kowalski R; Swoyer R; Galli J; Copeland V; Rios S; Davidson RC; Salnikova M; Kingsley S; Bryan J; Casimiro DR; Friedman HM J Virol; 2014 Feb; 88(4):2000-10. PubMed ID: 24284325 [TBL] [Abstract][Full Text] [Related]
10. Better neutralization of herpes simplex virus type 1 (HSV-1) than HSV-2 by antibody from recipients of GlaxoSmithKline HSV-2 glycoprotein D2 subunit vaccine. Awasthi S; Belshe RB; Friedman HM J Infect Dis; 2014 Aug; 210(4):571-5. PubMed ID: 24652496 [TBL] [Abstract][Full Text] [Related]
11. Protection from herpes simplex virus (HSV)-2 infection with replication-defective HSV-2 or glycoprotein D2 vaccines in HSV-1-seropositive and HSV-1-seronegative guinea pigs. Hoshino Y; Pesnicak L; Dowdell KC; Burbelo PD; Knipe DM; Straus SE; Cohen JI J Infect Dis; 2009 Oct; 200(7):1088-95. PubMed ID: 19702506 [TBL] [Abstract][Full Text] [Related]
12. Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection. Shlapobersky M; Marshak JO; Dong L; Huang ML; Wei Q; Chu A; Rolland A; Sullivan S; Koelle DM J Gen Virol; 2012 Jun; 93(Pt 6):1305-1315. PubMed ID: 22398318 [TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs. Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834 [TBL] [Abstract][Full Text] [Related]
14. [Construction and Immunogenicity Analysis of Herpes Simplex Virus Type 2 Glycoprotein D Recombinant Adenovirus Vaccine]. Liu W; Zhao D; Wang Z; Li Y; Wang H; Wang H Bing Du Xue Bao; 2016 May; 32(3):267-72. PubMed ID: 29962197 [TBL] [Abstract][Full Text] [Related]
15. Improving immunogenicity and efficacy of vaccines for genital herpes containing herpes simplex virus glycoprotein D. Awasthi S; Shaw C; Friedman H Expert Rev Vaccines; 2014 Dec; 13(12):1475-88. PubMed ID: 25138572 [TBL] [Abstract][Full Text] [Related]
16. Intranasal nanoemulsion-adjuvanted HSV-2 subunit vaccine is effective as a prophylactic and therapeutic vaccine using the guinea pig model of genital herpes. Bernstein DI; Cardin RD; Bravo FJ; Hamouda T; Pullum DA; Cohen G; Bitko V; Fattom A Vaccine; 2019 Oct; 37(43):6470-6477. PubMed ID: 31515143 [TBL] [Abstract][Full Text] [Related]
17. Immunization with recombinant varicella-zoster virus expressing herpes simplex virus type 2 glycoprotein D reduces the severity of genital herpes in guinea pigs. Heineman TC; Connelly BL; Bourne N; Stanberry LR; Cohen J J Virol; 1995 Dec; 69(12):8109-13. PubMed ID: 7494331 [TBL] [Abstract][Full Text] [Related]
18. Serum and Cervicovaginal Fluid Antibody Profiling in Herpes Simplex Virus-Seronegative Recipients of the HSV529 Vaccine. Wang K; Dropulic L; Bozekowski J; Pietz HL; Jegaskanda S; Dowdell K; Vogel JS; Garabedian D; Oestreich M; Nguyen H; Ali MA; Lumbard K; Hunsberger S; Reifert J; Haynes WA; Sawyer JR; Shon JC; Daugherty PS; Cohen JI J Infect Dis; 2021 Nov; 224(9):1509-1519. PubMed ID: 33718970 [TBL] [Abstract][Full Text] [Related]
19. Herpes simplex virus type 2 trivalent protein vaccine containing glycoproteins C, D and E protects guinea pigs against HSV-1 genital infection. Egan K; Hook LM; Naughton A; Friedman HM; Awasthi S Hum Vaccin Immunother; 2020 Sep; 16(9):2109-2113. PubMed ID: 32347775 [TBL] [Abstract][Full Text] [Related]
20. A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model. Awasthi S; Hook LM; Shaw CE; Friedman HM Hum Vaccin Immunother; 2017 Dec; 13(12):2785-2793. PubMed ID: 28481687 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]